Toronto-based Xandar Kardian’s Series A round was led by Phoenix Venture Partners, Portfolio Active Aging & Longevity Fund and Taronga Ventures, among others, according to a news release.
Xandar Kardian boasts that the XK300 autonomous health monitor is the world’s first and only commercially available, contact-free, continuous vital sign monitoring system. The XK300 gained FDA 510(k) clearance as a Class II medical device in April and has 32 patents granted and 11 pending.
The contactless vital sign monitor offers accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers, the company said. Its radar technology can smart-build implementation to provide commercial and public building operators with real-time occupancy measurements for effective energy optimization.
“Our radar-based solutions are the future of healthcare and patient monitoring, allowing providers to take continuous vital sign measurements without any intervention — a true breakthrough that will save lives,” Xandar Kardian Founder & CEO Sam Yang said in the release. “The funds raised in this financing round will support the commercial rollout of our healthcare solutions and the expansion of our RealTech business in a digital-first era.”
